10-Q: Dare Bioscience Faces Going Concern Amidst Q3 Losses

Dare Bioscience reported a significant net loss and increased cash burn in Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite strategic pivots and new grant funding.

Summary

• Reported a net loss of approximately $12.0 million for the nine months ended September 30, 2025, a significant increase from a net income of $1.5 million in the prior year, primarily due to the absence of a large one-time royalty sale.
• Experienced negative cash flow from operations of approximately $11.3 million for the nine months ended September 30, 2025, compared to positive cash flow of $0.2 million in the prior year.
• Cash and cash equivalents increased to $23.1 million as of September 30, 2025, from $15.7 million at December 31, 2024, largely driven by financing activities.
• Total stockholders' equity improved from a deficit of $(6.0) million at December 31, 2024, to a positive $2.9 million at September 30, 2025, primarily due to common stock issuances.
• Revenue for the nine months ended September 30, 2025, decreased by 91% to $6,517 from $73,431 in the prior year, consisting of non-cash royalty revenue.
• Research and development (R&D) expenses, net of contra R&D, decreased by 55% to $4.9 million for the nine months ended September 30, 2025, from $11.0 million in the prior year, largely due to increased grant funding offsetting costs.
• General and administrative (G&A) expenses remained stable at approximately $7.2 million for both nine-month periods.
• The company expanded its business model in March 2025 to include a dual-path approach: traditional FDA approval and earlier market access via Section 503B compounding, as well as consumer health products.
• DARE to PLAY Sildenafil Cream is expected to initiate commercialization in Q4 2025 via a Section 503B-registered outsourcing facility, with revenue not expected to be material in 2025.
• DARE to RECLAIM estradiol progesterone intravaginal ring is targeted for availability and revenue generation in early 2027 via Section 503B.
• A line of consumer health products, DARE to RESTORE vaginal probiotics, is targeted for U.S. availability in Q1 2026.
• Enrollment is ongoing for the Ovaprene pivotal Phase 3 clinical study, with completion anticipated in 2026; an interim analysis in July 2025 recommended continuation without modification, noting a 9% pregnancy rate and 17% discontinuation due to vaginal odor.
• Recruitment for the Ovaprene Phase 3 study at CCTN sites was paused in Q1 2025 due to uncertainty regarding the NICHD budget.
• Initiation of the first Phase 3 study for Sildenafil Cream, 3.6% (for FSAD) is delayed beyond 2025 due to ongoing FDA feedback on patient-reported outcomes (PRO) psychometrics.
• Received $6.0 million in July 2025 and $4.0 million in October 2025 from the Gates Foundation for the DARE-LARC1 program, bringing cumulative funding to $41.8 million out of a potential $49.0 million.
• Regained compliance with Nasdaq's stockholders' equity requirement on July 24, 2025, but is subject to a one-year mandatory monitoring period.

Sentiment

Score: 3

Explanation: While the company has strategic initiatives and significant grant funding, the substantial net loss, increased cash burn from operations, and explicit 'going concern' warning indicate a highly challenging financial position. Delays in key clinical trials and heavy reliance on future capital raises further underscore operational hurdles and financial instability, despite a positive shift in stockholders' equity driven by dilutive stock issuances.

Positives

• Cash and cash equivalents increased to $23.1 million as of September 30, 2025, from $15.7 million at December 31, 2024.
• Total stockholders' equity improved from a deficit of $(6.0) million at December 31, 2024, to a positive $2.9 million at September 30, 2025.
• Significant non-dilutive grant funding received, including $10.0 million from the Gates Foundation for DARE-LARC1 in July and October 2025, bringing total funding for this program to $41.8 million out of $49.0 million.
• Ovaprene Phase 3 study's Data Safety Monitoring Board (DSMB) recommended continuation without modification in July 2025, with no new safety or tolerability concerns identified.
• Regained compliance with Nasdaq's stockholders' equity listing requirement on July 24, 2025.
• Strategic expansion into Section 503B compounding and consumer health products aims to provide earlier market access and diversify revenue streams, with DARE to PLAY Sildenafil Cream expected to launch in Q4 2025.

Negatives

• Reported a net loss of approximately $12.0 million for the nine months ended September 30, 2025, a significant deterioration from a net income of $1.5 million in the prior year.
• Experienced negative cash flow from operations of approximately $11.3 million for the nine months ended September 30, 2025, compared to positive cash flow in the prior year.
• Revenue decreased by 91% for the nine months ended September 30, 2025, to $6,517, primarily due to the sale of XACIATO royalty rights in the prior year.
• Substantial doubt exists about the company's ability to continue as a going concern within the next 12 months.
• Initiation of the first Phase 3 study for Sildenafil Cream, 3.6% is delayed beyond 2025 due to ongoing FDA feedback, with no clear timeline for commencement.
• Recruitment for the Ovaprene Phase 3 study at CCTN sites was paused due to uncertainty regarding the NICHD budget, and these sites will not resume recruitment.
• Ovaprene Phase 3 interim analysis showed a 9% pregnancy rate and 17% discontinuation rate due to vaginal odor, which could impact efficacy and acceptability perceptions.
• The company has a history of losses from operations and an accumulated deficit of approximately $187.2 million as of September 30, 2025.
• Uncertainty regarding the timing and amount of potential revenue from new Section 503B compounding and consumer health products due to early stages of execution and lack of prior commercialization infrastructure.

Risks

• Inability to raise additional capital, under favorable terms or at all, or generate sufficient revenue from Section 503B compounding and consumer health products to fund operating needs and continue as a going concern.
• Dependence on grants and other financial awards from governmental entities and private foundations to advance product candidates.
• Inexperience, as a company, in and lack of infrastructure for commercializing products.
• Reliance on third parties to execute operating plans and business strategy, including commercialization and clinical studies.
• Difficulties or delays in commencement or completion, or the termination or suspension, of current or planned clinical or preclinical studies.
• Failure to complete development of product candidates or obtain FDA or foreign regulatory authority approval on projected timelines or budgets, or at all.
• Challenges and delays in obtaining timely supplies of product candidates, including components and finished products.
• The removal of sildenafil citrate or any other bulk drug substance from the FDA's list for Section 503B compounding.
• A change in the laws or regulations related to compounded drugs under Section 503B of the FDCA or consumer health products.
• Termination by a collaborator of out-license agreements for XACIATO and Ovaprene, or a decision by Bayer not to make the Ovaprene license grant fully effective.
• Uncertainty regarding the timing and amount of future royalty, milestone, or other payments under out-license agreements.
• Loss of, or inability to attract, key personnel.
• A change in the FDA's prior determination that the Center for Devices and Radiological Health would lead the review of a premarket approval application for Ovaprene.
• Unfavorable differences between preliminary, interim, or topline clinical study data and final study results.
• Failure to select product candidates that capitalize on the most scientifically, clinically, or commercially promising or profitable indications due to limited financial resources.
• Loss or impairment of in-licensed rights to develop and commercialize products and product candidates.
• Developments by competitors that make any product or potential product less competitive or obsolete.
• Unfavorable or unanticipated macroeconomic factors, geopolitical events or conflicts, public health emergencies, or natural disasters.
• Weak interest in women's health relative to other healthcare sectors from the investment community or potential collaborators.
• Cyber-attacks, security breaches, or similar events compromising technology systems and data.
• Difficulty in introducing branded products in a market made up of generic products.
• Inability to adequately protect or enforce intellectual property rights.
• Lack of patent protection for active ingredients in certain products, exposing them to competition.
• Higher risk of failure associated with product candidates in preclinical stages of development.
• Disputes or other developments concerning intellectual property rights.
• Failure to maintain the listing of common stock on the Nasdaq Capital Market, especially during the one-year monitoring period.
• Price and volume fluctuations in the stock market, which could cause investors to experience losses and subject the company to securities class-action litigation.
• Development of safety, efficacy, or quality concerns related to products or product candidates.
• Product liability claims or governmental investigations.
• Changes in government laws and regulations in the United States and other jurisdictions, including those governing research, development, approval, manufacturing, supply, distribution, pricing, and marketing.
• Increased costs as a result of operating as a public company and substantial time devoted by management to compliance initiatives and corporate governance practices.
• Adverse effects on business, financial condition, and operating results from evolving U.S. and global economic, political, and regulatory developments and conditions, such as inflation, high interest rates, and potential U.S. government shutdowns.
• Significant reductions in funding and staffing at federal agencies like the FDA and NIH, potentially leading to delays in regulatory processes and reduced grant funding.

Future Outlook

The company expects to initiate commercialization of DARE to PLAY Sildenafil Cream in Q4 2025, though revenue is not anticipated to be material in 2025. DARE to RESTORE vaginal probiotics are targeted for Q1 2026 U.S. availability, and DARE to RECLAIM estradiol progesterone intravaginal ring for early 2027. Enrollment for the Ovaprene Phase 3 study is expected to complete in 2026. The company will require additional capital to advance pipeline programs not supported by non-dilutive funding and to support long-term operating plans, and may continue to incur significant losses and negative cash flows for several years.

Management Comments

• "We are a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions."
• "Our goal is to fulfill that need by bringing innovative products to market as soon as practicable, whether as FDA-approved therapies or through alternative regulatory pathways that enable earlier availability, such as Section 503B compounding."
• "We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation."
• "We expect to begin recording revenue from sales thereof in the fourth quarter of 2025, however, we do not expect the amount of such revenue, if any, to be material during 2025." (referring to DARE to PLAY Sildenafil Cream)
• "Because we are in the early stages of executing against our Section 503B compounding strategy and, as an organization, we have no experience in or infrastructure for commercializing products, the amount of potential revenue we may generate during 2026 remains uncertain."
• "We anticipate needing to invest no more than $1.0 million to launch DARE to PLAY Sildenafil Cream in 2025."
• "By pursuing a balanced strategy that integrates short-term commercial execution with long-term R&D investment, we aim to reduce reliance on dilutive capital and build a financially sustainable model for innovation in women's health."
• "We do not anticipate initiating the first Phase 3 study [for Sildenafil Cream] in 2025 and cannot at this time reasonably predict when the study will commence."
• "Based on our current analysis of the conditions described above, there is substantial doubt about our ability to continue as a going concern within the 12-month period from the issuance date of the accompanying condensed consolidated financial statements."

Industry Context

The company operates in the women's health biotech sector, focusing on underserved areas like contraception, sexual health, and vaginal health. Its strategic shift to a dual-path approach, including Section 503B compounding and consumer health products, reflects an industry trend towards faster market access and diversified product offerings beyond traditional FDA pathways. The reliance on non-dilutive grant funding for R&D is a common strategy for early-stage biotechs. However, the company faces broader industry challenges such as macroeconomic uncertainty, potential reductions in federal research funding (NIH), and intense competition in the pharmaceutical and biopharmaceutical industries.

Comparison to Industry Standards

• DARE to PLAY Sildenafil Cream is positioned as a 'first-of-its-kind' topical sildenafil product for female sexual arousal disorder, claiming no other topical cream sildenafil products are manufactured under cGMP with supporting clinical data demonstrating rapid genital blood flow increase and arousal improvements using validated endpoints.
• DARE to RECLAIM estradiol progesterone intravaginal ring addresses an unmet need, as there are 'no FDA-approved products that provide estradiol and progesterone together in a non-oral monthly form.'
• The company's financial performance, particularly the significant net loss and negative cash flow from operations, contrasts with more established pharmaceutical companies that typically generate substantial revenue and profits from approved products. Its reliance on grant funding and equity raises for operations is typical of a development-stage biotech, but the explicit 'going concern' warning indicates a more precarious financial position compared to peers with stronger pipelines or commercialized assets.
• No specific comparable companies, projects, or results are detailed in the filing for direct benchmarking against industry standards beyond the 'first-of-its-kind' and 'no FDA-approved products' statements.

Corporate Governance

Legal Proceedings

• Management is not aware of any material claims, disputes, or unsettled matters that would have a material adverse effect on the company's results of operations, liquidity, or financial position that have not been adequately provided for.

Related Party Transactions

• In January 2024, the company entered into a consulting agreement with its former Chief Financial Officer to assist in transition matters, paying $31,667 per month for a nine-month period and reimbursing up to $500 per month for health insurance premiums.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing equity raises, potential delisting risk if Nasdaq compliance is not maintained, and substantial uncertainty regarding future profitability and stock value due to the going concern warning and operational losses.
• **Employees:** Potential impact on morale and retention due to financial instability and the going concern warning, though stock-based compensation plans are in place to incentivize.
• **Customers (future):** Potential for new products (DARE to PLAY, DARE to RESTORE, DARE to RECLAIM) to address unmet needs in women's health, offering new treatment and wellness options.
• **Suppliers/Collaborators:** Continued reliance on third parties for manufacturing, clinical trials, and commercialization, with potential for delays or renegotiations if financial stability deteriorates.
• **Creditors:** Increased risk due to the going concern warning and the company's history of losses, potentially impacting terms for future debt financing.

Next Steps

• Initiate commercialization of DARE to PLAY Sildenafil Cream in Q4 2025 via a Section 503B-registered outsourcing facility.
• Expand commercial portfolio with the introduction of DARE to RESTORE vaginal probiotic products in Q1 2026.
• Target availability and revenue generation for DARE to RECLAIM estradiol progesterone intravaginal ring in early 2027.
• Continue enrollment in the Ovaprene pivotal Phase 3 clinical study, with completion anticipated in 2026.
• Engage with the FDA to align on the Phase 3 program for Sildenafil Cream, 3.6% following additional input and information requests.
• Advance development of product candidates supported by non-dilutive grant funding, particularly DARE-LARC1 and DARE-HPV.
• Evaluate and pursue various capital raising options, including sales of equity, debt financings, government or other grant funding, collaborations, structured financings, and commercial collaborations or other strategic transactions.
• Monitor compliance with Nasdaq listing requirements during the one-year mandatory monitoring period from July 24, 2025.

Key Dates

Recommendation

The filing presents a highly concerning financial picture, with a significant net loss, substantial negative cash flow from operations, and an explicit 'going concern' warning. While the company has strategic initiatives and has secured grant funding, these positives are overshadowed by the fundamental financial instability and delays in key clinical programs. The reliance on continuous dilutive capital raises, coupled with the uncertainty of future revenue from new commercialization strategies, indicates a high-risk investment. The Nasdaq monitoring period adds further pressure. A seasoned investor would view the 'going concern' warning as a critical red flag, suggesting a strong likelihood of further value erosion and potential for significant losses.

Keywords

Women's Health, Biotech, Pharmaceuticals, Contraception, Sexual Health, Pelvic Pain, Fertility, Infectious Disease, Vaginal Health, Menopause, FDA Approval, Section 503B Compounding, Clinical Trials, Preclinical Development, Grant Funding, Ovaprene, Sildenafil Cream, DARE-LARC1, XACIATO, Nasdaq Listing